Literature DB >> 33544244

Cytokine "fine tuning" of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies.

Tobias Russell1, Charlie Bridgewood1, Hannah Rowe1, Ala Altaie1, Elena Jones1, Dennis McGonagle2,3.   

Abstract

A curious feature of axial disease in ankylosing spondylitis (AS) and related non-radiographic axial spondyloarthropathy (nrAxSpA) is that spinal inflammation may ultimately be associated with excessive entheseal tissue repair with new bone formation. Other SpA associated target tissues including the gut and the skin have well established paradigms on how local tissue immune responses and proven disease relevant cytokines including TNF and the IL-23/17 axis contribute to tissue repair. Normal skeletal homeostasis including the highly mechanically stressed entheseal sites is subject to tissue microdamage, micro-inflammation and ultimately repair. Like the skin and gut, healthy enthesis has resident immune cells including ILCs, γδ T cells, conventional CD4+ and CD8+ T cells and myeloid lineage cells capable of cytokine induction involving prostaglandins, growth factors and cytokines including TNF and IL-17 that regulate these responses. We discuss how human genetic studies, animal models and translational human immunology around TNF and IL-17 suggest a largely redundant role for these pathways in physiological tissue repair and homeostasis. However, disease associated immune system overactivity of these cytokines with loss of tissue repair "fine tuning" is eventually associated with exuberant tissue repair responses in AS. Conversely, excessive biomechanical stress at spinal enthesis or peripheral enthesis with mechanically related or degenerative conditions is associated with a normal immune system attempts at cytokine fine tuning, but in this setting, it is commensurate to sustained abnormal biomechanical stressing. Unlike SpA, where restoration of aberrant and excessive cytokine "fine tuning" is efficacious, antagonism of these pathways in biomechanically related disease may be of limited or even no value.

Entities:  

Keywords:  Enthesis; IL-17; Spondyloarthritis; TNF

Mesh:

Substances:

Year:  2021        PMID: 33544244      PMCID: PMC7990848          DOI: 10.1007/s00281-021-00836-1

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   11.759


  111 in total

Review 1.  An enthesitis based model for the pathogenesis of spondyloarthropathy. additive effects of microbial adjuvant and biomechanical factors at disease sites.

Authors:  D McGonagle; L Stockwin; J Isaacs; P Emery
Journal:  J Rheumatol       Date:  2001-10       Impact factor: 4.666

Review 2.  Wound repair at a glance.

Authors:  Tanya J Shaw; Paul Martin
Journal:  J Cell Sci       Date:  2009-09-15       Impact factor: 5.285

3.  Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.

Authors:  Joachim Sieper; Atul Deodhar; Helena Marzo-Ortega; Jacob A Aelion; Ricardo Blanco; Tseng Jui-Cheng; Mats Andersson; Brian Porter; Hanno B Richards
Journal:  Ann Rheum Dis       Date:  2016-08-31       Impact factor: 19.103

4.  IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis.

Authors:  J C Martin; G Bériou; M Heslan; C Bossard; A Jarry; A Abidi; P Hulin; S Ménoret; R Thinard; I Anegon; C Jacqueline; B Lardeux; F Halary; J-C Renauld; A Bourreille; R Josien
Journal:  Mucosal Immunol       Date:  2015-09-02       Impact factor: 7.313

5.  Ruptured Tendons in Anabolic-Androgenic Steroid Users: A Cross-Sectional Cohort Study.

Authors:  Gen Kanayama; James DeLuca; William P Meehan; James I Hudson; Stephanie Isaacs; Aaron Baggish; Rory Weiner; Lyle Micheli; Harrison G Pope
Journal:  Am J Sports Med       Date:  2015-09-11       Impact factor: 6.202

6.  Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials.

Authors:  Runsheng Wang; Abhijit Dasgupta; Michael M Ward
Journal:  Ann Rheum Dis       Date:  2015-08-06       Impact factor: 19.103

7.  A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis.

Authors:  Eva Balazcs; Joachim Sieper; Kara Bickham; Anish Mehta; Nancy Frontera; Paul Stryszak; Zoran Popmihajlov; Paul M Peloso
Journal:  BMC Musculoskelet Disord       Date:  2016-10-13       Impact factor: 2.362

Review 8.  Cartilage and bone damage in rheumatoid arthritis.

Authors:  Monika Ostrowska; Włodzimierz Maśliński; Monika Prochorec-Sobieszek; Michał Nieciecki; Iwona Sudoł-Szopińska
Journal:  Reumatologia       Date:  2018-05-09

9.  Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Authors:  Dominique Baeten; Mikkel Østergaard; James Cheng-Chung Wei; Joachim Sieper; Pentti Järvinen; Lai-Shan Tam; Carlo Salvarani; Tae-Hwan Kim; Alan Solinger; Yakov Datsenko; Chandrasena Pamulapati; Sudha Visvanathan; David B Hall; Stella Aslanyan; Paul Scholl; Steven J Padula
Journal:  Ann Rheum Dis       Date:  2018-06-26       Impact factor: 19.103

Review 10.  The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science.

Authors:  Abdulla Watad; Charlie Bridgewood; Tobias Russell; Helena Marzo-Ortega; Richard Cuthbert; Dennis McGonagle
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

View more
  3 in total

Review 1.  Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis.

Authors:  Dennis McGonagle; Abdulla Watad; Kassem Sharif; Charlie Bridgewood
Journal:  Front Immunol       Date:  2021-03-19       Impact factor: 7.561

Review 2.  Regulation of the mesenchymal stem cell fate by interleukin-17: Implications in osteogenic differentiation.

Authors:  Jelena Krstić; Slavko Mojsilović; Sonja S Mojsilović; Juan F Santibanez
Journal:  World J Stem Cells       Date:  2021-11-26       Impact factor: 5.326

Review 3.  The Potential Role of Genetics, Environmental Factors, and Gut Dysbiosis in the Aberrant Non-Coding RNA Expression to Mediate Inflammation and Osteoclastogenic/Osteogenic Differentiation in Ankylosing Spondylitis.

Authors:  Hsien-Tzung Liao; Chang-Youh Tsai; Chien-Chih Lai; Song-Chou Hsieh; Yi-Syuan Sun; Ko-Jen Li; Chieh-Yu Shen; Cheng-Han Wu; Cheng-Hsun Lu; Yu-Min Kuo; Tzu-Hao Li; Chung-Tei Chou; Chia-Li Yu
Journal:  Front Cell Dev Biol       Date:  2022-01-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.